February 28, 2008
Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has received allowance of its patent applications in Europe and China covering diagnostic use of PV-10 and a number of related agents in CT and MRI imaging. The pending patents cover products for diagnosis of cancer and other serious diseases.
“These cases augment our international portfolio of twenty-six issued patents and four pending patents, along with our U.S. patent portfolio of sixteen issued and five pending patents,” said Craig Dees, PhD, CEO of Provectus Pharmaceuticals. “As important milestones, they demonstrate the scope of our patent activity that spans markets ranging from the developed world to the rapidly developing world.”
Read the rest of this press release on Provectus Pharmaceuticals pharma patent.
pharma patent
pharma patent
February 25, 2008
Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of autoimmune and gastrointestinal diseases, announced that the United States Patent and Trademark Office has issued two key patents, 7,320,788 and 7,303,871, covering gluten detoxification with proline specific prolyl endopeptidases (PEPs) and with mixtures of a PEP and a glutamine specific protease. Alvine has an exclusive worldwide license to these patents under an agreement with Stanford University. Both patents provide important protection for ALV003, Alvine’s lead product currently in clinical development for use in the treatment of celiac disease.
“Alvine is delighted that these two patents have issued,” said Dr. Abhay Joshi, Alvine’s President and Chief Executive Officer. “Alvine and others have shown PEPs to be efficient at degrading gluten. With these patents and our recently announced initiation of clinical trials of ALV003 (a combination of a PEP and a glutamine specific protease), we believe Alvine is well positioned to capitalize on the potential use of proteases as therapeutic agents to treat celiac disease. ALV003 is more efficient at degrading gluten than either a PEP or a glutamine specific protease alone.”
Read the rest of this article on Alvine Pharmaceuticals’ pharma patent.
pharma patent
pharma patent
Pierre Verstraete
February 5, 2008
Latin America has room for improvement in fostering environments where intellectual property is respected, particularly with regard to patented pharmaceuticals. On many occasions, in fact, countries still reward the copying of patented drugs rather than the development of innovative life-saving medicines. Pharmaceutical innovation, however, is undeniably in the interest of Latin America and its patients, and countries in the region should take concrete steps to create the conditions that foster it, including strong and effective intellectual property protection.
Already a success story is Mexico, which has greatly benefited from the intellectual property protection provided through the North American Free Trade Agreement (NAFTA). Today, Mexico is the leading pharmaceutical market in the region. In part, owing to Mexico’s decision to protect intellectual property, pharmaceutical patents and foreign direct investment in the pharmaceutical sector have grown and are expected to grow further.
Strong patent and data protection for pharmaceuticals is good for patients and important for research-based companies like Schering-Plough Corporation. New medicines are developed and medical breakthroughs occur when companies take large and enormously expensive risks. By providing a limited period during which our products may not be copied, intellectual property protection gives Schering-Plough and its investors the incentive to take those big risks. This is the engine that propelled some of the great advances in human health in this century, including treatments for deadly infections, heart disease and cancer.
This engine also drives Latin America’s home-grown industries that rely on intellectual property protection for risky investments. Local pharmaceutical companies use the incentives afforded by strong patents and effective data protection to overcome the risks inherent in the development of innovative drugs. For instance, the medicinal properties of the flora and fauna in Brazil’s tropical forests were well-known long before Brazil’s decision to strengthen intellectual property protection in the mid-1990s. But it was only with the introduction of such protection that Brazilian researchers felt secure enough to take the risks that resulted in innovative, patent-protected biomedical products developed in Brazil for global use—a good result for Brazilian companies, the Brazilian economy, and Brazilian patients alike.
Read the rest of this article on the benefits of pharmaceutical patents.
Pharmaceutical Patents
pharmaceutical patents
